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Abstract 1 
Progression of prostate cancer is highly dependent upon the androgen receptor pathway, such that 2 
knowledge of androgen-regulated proteins is vital to understand and combat this disease.  Using a 3 
proteomic screen, we found the RNA-binding protein FUS/TLS (Fused in Ewing’s 4 
Sarcoma/Translocated in Liposarcoma) to be down-regulated in response to androgen.  FUS has 5 
recently been shown to be recruited by non-coding RNAs to the regulatory regions of target genes 6 
such as Cyclin D1, where it represses transcription by disrupting complex formation.  Here we show 7 
that FUS has some characteristics of a putative tumor suppressor, since its over-expression 8 
promoted growth inhibition and apoptosis of prostate cancer cells, whereas its knock-down 9 
increased cell proliferation.  This effect was reproducible in vivo, such that increasing FUS levels in 10 
tumor xenografts led to dramatic tumour regression. Further, FUS promoted conditions that favored 11 
cell cycle arrest by reducing the levels of proliferative factors such as cyclin D1 and Cdk6 and by 12 
increasing levels of the anti-proliferative Cdk inhibitor p27. Immunohistochemical analysis 13 
revealed that FUS expression is inversely correlated with Gleason grade, demonstrating that 14 
patients with high levels of FUS survived longer and were less likely to have bone metastases, 15 
suggesting that loss of FUS expression may contribute to cancer progression.  Taken together, our 16 
results address the question of how androgens regulate cell cycle progression, by demonstrating that 17 
FUS is a key link between androgen receptor signalling and cell cycle progression in prostate 18 
cancer.  19 
 20 
21 
 4
Introduction 1 
Prostate cancer is almost invariably dependent upon the androgen receptor (AR) pathway, which 2 
when activated stimulates cell proliferation.  Several factors involved in cell cycle progression are 3 
regulated in response to androgen - for example Cyclin D1, which is up-regulated (1-3).  Non 4 
organ-confined prostate cancer is treated with analogues of luteinizing hormone releasing hormone 5 
(LHRH), which block androgen production, and/or antiandrogens, which bind to the AR and hold it 6 
in an inactive state.  Although initially successful, these treatments consistently fail and the tumors 7 
progress to a more aggressive hormone-refractory stage for which few therapeutic options exist. 8 
Expression of the AR is maintained in this refractory stage and much evidence exists to suggest that 9 
the receptor is still driving growth (4).  Downstream targets of the AR involved in cell growth are 10 
therefore important in terms of further characterising this disease and identifying new therapeutic 11 
targets.  12 
 FUS (Fused in Ewing’s Sarcoma), also known as TLS (Translocated in Liposarcoma), is a 13 
member of the TET family, along with Ewing’s Sarcoma (EWS) and TATA-binding protein-14 
associated factor TAF15/TAFII68 (5).  These family members, which are structurally and 15 
functionally related, are defined by the presence of an N-terminal SYGQ-rich region, a C2/C2 zinc 16 
finger motif, an RNA-recognition motif and at least one RGG-repeat region (6).  FUS was 17 
originally identified in human myxoid and round cell liposarcomas as an oncogenic fusion with the 18 
stress-induced DNA-binding transcription factor CHOP (CCAAT enhancer-binding homologous 19 
protein) (7, 8). FUS is a multi-functional protein, being implicated in pre-mRNA splicing (9), 20 
chromosome stability (10), cell spreading (11) and transcription (12, 13). Recently, FUS has been 21 
shown to be directed to the regulatory regions of target genes by single stranded non-coding RNA 22 
(ncRNA) transcripts tethered to DNA; repressing transcription by binding to and inhibiting 23 
complexes bound to such elements (12). This suggests that ncRNAs, via recruitment of RNA-24 
binding proteins such as FUS, can act cooperatively as selective ligands to regulate transcription.  25 
 Here we show that FUS is an AR target protein down-regulated in response to androgen.  26 
 5
Over-expression of FUS significantly retards androgen-induced prostate cancer cell growth in vitro 1 
and in vivo, regulates the expression of several factors involved in cell cycle progression (for 2 
example cyclin D1), and induces G1 arrest and apoptosis.  FUS therefore exhibits certain 3 
characteristics of a tumor suppressor. Immunohistochemistry performed upon human tissue arrays 4 
demonstrated that FUS expression is inversely correlated with prostate tumor grade, and that 5 
patients with high levels of FUS have longer survival rates and are less likely to have bone 6 
metastases and hence we surmise that loss of FUS expression is important in disease progression. 7 
 8 
Methods 9 
 10 
Cell culture. LNCaP cells (ATCC CRL-1740) were obtained in 2003 from American Type Culture 11 
Collection (Manassas, VA, USA), where they are verified phenotypically and by short tandem 12 
repeat profiling, frozen in liquid nitrogen and fresh aliquots defrosted for use every 4-6 months.  13 
Cell were grown in RPMI 1640 media as described previously (14) and their identity further 14 
verified at least every 1-2 months by testing for morphology (microscopic inspection), AR 15 
expression (immunoblotting), hormone sensitivity (reporter or PSA assay) and mycoplasma 16 
contamination (MycoAlert, Lonza, Basel, Switzerland). The LNCaP/TR2 (15) and LNCaP/TR2-17 
FUS lines were grown in RPMI 1640 media supplemented with 10% TET-free fetal calf serum 18 
(Clontech, Mountain View, CA), in the presence of the relevant antibiotics for selection purposes. 19 
Seventy-two hours before exposure to ligand, media were replaced with phenol red-free RPMI, 20 
supplemented with 2mM L-glutamine, 100 U/ml penicillin, 100 mg/ml streptomycin (Sigma-21 
Aldrich, St. Louis, MO) and 5% charcoal stripped fetal bovine serum (Labtech International, East 22 
Sussex, UK).   23 
 24 
2D-SDS PAGE. Four samples were prepared per experimental condition. Cells were incubated with 25 
ligand for 16 hours before lysis and proteins separated by 2D-SDS PAGE as previously described 26 
 6
(14).  Gels were stained using Sypro-ruby (GE Healthcare, Waukesha, WI) and spots detected using 1 
PDQuest version 8 (Bio-rad Hemel Hempstead, UK).  Spots found to be significantly regulated 2 
between treatments were excised and sequenced using Mass Spectrometry as previously described 3 
(16). 4 
  5 
Generation of stable cells inducibly expressing FUS cell line. For insertion of FUS in to the 6 
pCDNA4-TO plasmid, FUS was amplified by PCR with the addition of Bam HI and Xho I 7 
restriction sites (for 5’-GGA TCC ATG GCC TCA AAC GAT TAT ACC C-3’, rev 5’- CTC GAG 8 
TTA ATA CGG CCT CTC CCT GC-3’).  Both the plasmid and PCR product were digested with 9 
Bam HI and Xho I before ligation and subsequently verified by sequencing.  The pCDNA4-TO-FUS 10 
plasmid was stably transfected in to the LNCaP/TR2 line as previously described (15, 17). 11 
 12 
Depletion of FUS levels using siRNA. FUS levels were reduced in LNCaP cells, using a 13 
Dharmacon On-Target siRNA pool (L-009497-00-0005, Thermo Scientific, Lafayette, CO) as 14 
previously described (18).  To calculate percentage knock-down, densitometry was performed using 15 
Image J (NIH). FUS levels were normalized to β-actin and expressed as a percentage of FUS levels 16 
following treatment with siRNA-scrambled.  17 
 18 
Real-time quantitative PCR.  Cells were treated for the indicated times and RNA harvested using 19 
Qiashredders and RNEasy kits (Qiagen Ltd., Valencia, CA).  500ng of RNA was reverse 20 
transcribed using the SuperScript First-Strand Synthesis System (Invitrogen, Carlsbad, CA).  Gene 21 
expression was quantified using quantitative real-time PCR on a Taqman 7900HT (Applied 22 
Biosystems, Foster City, CA) (18). 23 
 24 
Western blotting. Cells were lysed in RIPA buffer and protein concentration determined by DC 25 
protein assay (Bio-Rad, Hertfordshire, UK).  15μg of protein was separated on a 10% SDS 26 
 7
polyacrylamide gel and electrophoretically transferred (Transblot, Bio-Rad) onto nitrocellulose 1 
membrane.  Membranes were blocked for 30min in PBS-0.5% Tween containing 5% non-fat milk 2 
powder followed by 1hr incubation with primary antibody against: FUS (4H11), Cyclin E1 (HE-3 
12), CDK2 (M2) and p27(C-19) were from Santa Cruz Biotechnology (Santa Cruz, Ca); β-actin 4 
(AC-15) and Cyclin D1 (ab24249) were from Abcam (Cambridge, UK); cleaved PARP (Asp214) 5 
was from Cell Signalling Technology (Danvers, MA); retinoblastoma (554162) was from BD 6 
Biosciences (San Jose, Ca); phosphospecific antibody for retinoblastoma Rb-pSer807/811 was from 7 
Sigma-Aldrich (R6400, Sigma-Aldrich); cyclin A2  (E23-1) was a kind gifts from Dr Gordon Peters 8 
(CRUK LRI, London, UK).Membranes were washed 3x with PBS-Tween and incubated for a 9 
further hour with the relevant secondary antibody (Dako, Carpinteria, CA).  Three washes with 10 
PBS-T and one wash with PBS were performed before chemiluminescent detection using ECL-11 
PLUS (GE Healthcare, Piscataway, NJ). 12 
 13 
Cell cycle analysis.  Cells were washed with PBS, trypsinized and pelleted (1200 rpm, 5min).  After 14 
2 washes with PBS, cells were fixed in 70% ethanol (overnight at 4°C).  Cells were washed 3 times 15 
with PBS before incubation for 1hr with 50mg/ml propidium iodide and 50mg/ml RNAse A in 16 
PBS. FACS analysis was carried out using a Becton-Dickinson (Franklin Lakes, NJ) FACS Calibur 17 
machine using linear scale representation of forward and side scatter during flow analysis. A total 18 
of 10,000 events were measured per sample. 19 
 20 
Growth and Caspase Assays.  LNCaP-FUS and the parental LNCaP-TR2 cells were seeded at 1000 21 
per well on a 96 well plate in 'stripping media' and left for 24hrs. Cells were treated ± mibolerone 22 
and ± doxycyline for the indicated times. Changes in cell proliferation were quantified using WST1 23 
assay (Roche), following the manufacturers instructions. Simultaneous plates were assayed for 24 
evidence of caspase 3/7 activity using Caspase-Glo assays (Promega, Madison, WI) and activity 25 
normalized for cell proliferation.  26 
 8
 1 
Chromatin Immunoprecipitation. LNCaP cells were grown to approximately 70% and serum 2 
starved for 72 h. Cells were treated 0, 2 or 24 hrs with 10nM mibolerone before cross-linking with 3 
formaldehyde (Sigma) for 10 min at RT. ChIP was performed using the Millipore Chromatin 4 
Immunoprecipitation Kit (Millipore, Billerica, MA) following the manufacturer’s instructions, with 5 
the exception that a protein A/G sepharose mix was used. DNA was recovered by phenol-6 
chloroform extraction and real-time quantitative PCR used to quantitate enrichment of regions of 7 
the CCND1 promoter. A: for - 5'-CTCCACCTCACCCCCTAAATC-3', rev - 5'-8 
AGAGCCCAAAAGCCATCC-3'; C: for - 5'-CCGACTGGTCAAGGTAGGAAG-3', rev: 5'-9 
ACAACCCCTGTGCAAGTTTC-3'; D: for - 5'-GGGACCCTCTCATGTAACCA-3', rev - 10 
5'GAGCCGGCATAATTCAGAAC3' (12). 11 
 12 
Tissue microarray and immunohistochemistry. Immunohistochemistry was performed using 3 13 
tissue microarrays (TMAs) of benign and malignant prostate biopsies derived from transrectal 14 
biopsy, transurethral resection, and radical prostatectomy as previously described (19). All 15 
materials were used in accordance with approval granted by the Northumberland, Tyne and Wear 16 
NHS Strategic Health Authority Research Ethics Committee (reference 2003/11; The Freeman 17 
Hospital). The final study included 321 cancer biopsies and 69 benign biopsies. Antigen retrieval 18 
was achieved by immersion in 10 mmol/L citric acid buffer (pH 6.0), followed by microwaving for 19 
15 min (at 1,000 W) in a pressure cooker. Sections were immunostained with a rabbit polyclonal 20 
antibody against FUS (Santa Cruz Biotechnology) on a DAKO autostainer using Vectastain ABC 21 
kits (Vector Labs), according to the manufacturer's protocol. Sections known to stain positively 22 
were included in each batch, and negative controls were prepared by replacing the primary antibody 23 
with TBS buffer. FUS expression was scored blindly for epithelial nuclear intensity of staining and 24 
number of epithelial nuclei positive per field, in each biopsy core. Slides were scanned using a 25 
Scanscope GL scanner (Aperio) and analysed using SpectrumTM software (Aperio). For statistical 26 
 9
analysis, samples were split into low or high intensity/number of positive nuclei (low = 0, 1 and 1 
high = 2, 3). 2 
 3 
In vivo xenograft model. 2x106 LNCaP-FUS cells mixed with an equal volume of matrigel (BD 4 
Biosciences, San Jose, Ca) were injected subcutaneously into the flanks of castrated male balb/c 5 
nude mice (Harlan Laboratories, Indianapolis, IN).  Animals received bi-daily testosterone 6 
replacement injections until the tumors were established, following which the mice were split into 7 
experimental groups: ± doxycycline and ± testosterone.  Tumors were measured using calipers and 8 
relative tumor volume (RTV) calculated as previously described (20). After sacrifice, tumours were 9 
resected and immunohistochemistry performed as previously described (20) using antibodies 10 
specific for phospho-histone H3 (Ser10, Millipore, Billerica, MA), active Caspase 3 (AF835, R&D 11 
Systems, Minneapolis, MN) and cleaved PARP (Asp214, Cell Signalling Technology, Beverly, 12 
MA). 13 
 14 
Results 15 
FUS is down-regulated by androgen treatment. To identify targets regulated by the androgen 16 
receptor, a 2D-proteomic screen was performed on the AR positive LNCaP prostate cancer cell line, 17 
which is dependent on androgen for growth, treated with mibolerone (a synthetic androgen) or 18 
vehicle for 16 hours.  Proteins were separated using 2D SDS-PAGE, stained with Sypro-Ruby and 19 
spots found to have a significant change in density in response to androgen excised and identified 20 
using mass spectrometry. A spot found to be down-regulated in response to androgen, running at 21 
around 75kDa and pI 9.4, was identified as FUS (Figure 1A). To confirm androgen regulation of 22 
FUS expression, the LNCaP line was treated with androgen for 0-72 hours and immunoblotting 23 
performed (Figure 1B). FUS expression was found to be reduced by more than 90% after 72 hours 24 
of stimulation with androgen. This regulation appears to be at least partly at the RNA level since 25 
qRT-PCR demonstrated a significant decrease in FUS over a 72 hour time course (56% reduction at 26 
 10
72 hours) (Figure 1C) - as a control, expression of the known androgen regulated gene prostate 1 
specific antigen (PSA) was measured and increased transcription in response to androgen was 2 
confirmed.  C-jun has been previously shown to regulate FUS degradation (21), and hence we 3 
investigated whether this post-transcriptional regulation was also important in the androgen induced 4 
down-regulation of FUS. In accordance with this hypothesis, and in agreement with the work of 5 
Perrotti et al. (21), we found that c-jun expression was androgen-dependent, with upregulation of c-6 
jun protein evident within 8 hours of androgen treatment (Supplemental Figure 1A), preceding the 7 
decrease in FUS.  However, reducing c-jun levels by siRNA or treating cells with the protease 8 
inhibitor lactacystin did not affect the androgen-induced down-regulation of FUS (Supplemental 9 
Figures 1B, 1C).  We therefore surmise that the androgen dependent regulation of FUS is 10 
independent of c-jun and proteasomal degradation and is instead predominantly regulated at the 11 
transcriptional level. 12 
 13 
FUS represses LNCaP growth.  Since androgen treatment results in both prostate cell proliferation 14 
and a reduction in FUS expression, we tested the hypothesis that FUS is a suppressor of growth.  To 15 
investigate this, we created a stable cell line to allow doxycycline-inducible over-expression of 16 
FUS.  Addition of doxycycline led to an increase in FUS expression, with maximal expression at 17 
10nM and within 24 hours (Supplemental Figure 2). Light microscopy revealed that this exogenous 18 
FUS expression results in cell rounding within 4 days and a marked reduction in cell number by day 19 
6 (Figure 2A, top).  To quantify this, growth assays were performed over the same time-course.  In 20 
the absence of ligand little proliferation was evident, whereas addition of mibolerone resulted in a 21 
6-fold increase in proliferation after 8 days (Figure 2A, bottom).  Exogenous FUS expression in the 22 
presence of ligand resulted in a decrease in cell number, with fewer cells present after 8 days than 23 
were seeded.  To ensure that these effects were not an artefact of doxycycline treatment, growth 24 
assays were performed on the parental cells (LNCaP-TR2), which were unaffected by doxycycline 25 
treatment, demonstrating that the inhibition of androgen-stimulated growth is as a result of FUS 26 
 11
over-expression (Figure 2A).  To investigate the effect of FUS upon cell cycle progression, cells 1 
were propidium iodide (PI) stained and analysed using FACs.  In agreement with previous studies 2 
(for example (2, 14)), in the absence of ligand LNCaP cells were found to arrest in G1 phase 3 
(Figure 2B, C). Addition of ligand resulted in cells progressing through to S/G2/M.  In the presence 4 
of mibolerone, exogenous FUS resulted in a large increase sub-G1 peak (from 1.9% of cells to 4.3% 5 
at 4 days and from 2.7% to 31% at 8 days, Supplemental Table 1 and Figure 4A).  Analysis of the 6 
FACs data with the sub-G1 population removed (to avoid skewing the data) revealed that 7 
exogenous FUS expression (addition of doxycycline) blocks the action of androgen, resulting in an 8 
increase in cells in G1 and reducing the percentage of cells progressing to S and G2/M (Figure 2C).  9 
FACs analysis of the parental LNCaP-TR2 showed no change in cell cycle profile in response to 10 
doxycycline (Figure 2C and Supplementary Figure 2), confirming that these differences are as a 11 
result of increased FUS levels. 12 
To establish the role of FUS in androgen-induced growth we performed the reciprocal 13 
experiment, reducing FUS expression using transiently transfected siRNA. LNCaP cells were 14 
transfected with siRNA, successful knock-down was confirmed at the levels of RNA (93%) and 15 
protein (74%) (Supplemental Figure 4), and growth analysed at 3 and 6 days in response to different 16 
concentrations of mibolerone (Figure 2D).  After 3 days, reduction of FUS expression resulted in a 17 
significant increase in growth at the highest concentration (10nM) of ligand. After 6 days this 18 
growth-promoting effect was significant at both 1nM and 10nM mibolerone. 19 
 20 
FUS regulates the expression of factors involved in cell cycle progression Previously it has been 21 
shown that FUS is a negative regulator of cyclin D1 expression in RAW264.7 cells (12).  We were 22 
therefore interested to see whether increasing FUS expression in the LNCaP line altered the 23 
expression of cell cycle regulators, either directly or (since cyclin D1 is also androgen-regulated 24 
(22-24)) perhaps via preventing androgen-induced changes, which could potentially explain G1 25 
accumulation and growth inhibition.  Western blotting of lysates from the LNCaP-FUS line 26 
 12
demonstrated that increasing FUS levels altered the expression levels of several factors involved in 1 
G1 progression (Figure 3A).  Specifically, cyclin D1 and CDK6 levels were decreased in response 2 
to FUS over-expression, whereas the level of the kinase inhibitor p27 was increased. Little change 3 
was observed in levels of the other cell cycle regulators investigated and levels of the AR were also 4 
found to remain unchanged. This indicates that the effects of FUS on growth are at least in part due 5 
to it promoting G1 arrest, possibly via regulation of cyclin D1, CDK6 and p27. 6 
Wang et al. have previously demonstrated that FUS binds, via non-coding RNA, to the 7 
regulatory regions of Cyclin D1 and blocks transcription (12). In agreement with their study, the 8 
regulation of cyclin D1 by FUS in these prostate cancer cells appears to be at the transcriptional 9 
level, since over-expression or knock-down of FUS respectively reduces or enhances androgen-10 
induced cyclin D1 expression at the RNA level (Figure 3B).  Further, we performed ChIP on the 11 
CCND1 promoter to analyse FUS recruitment to two regions demonstrated by Wang et al. to 12 
express ncRNA (regions A and D) and one negative region that has been shown not to express 13 
ncRNA (region C) (12) (Figure 3D). FUS was found to bind to regions A and D but not C, and 14 
binding was only evident in the absence of androgen, supporting our hypothesis that, in prostate 15 
cancer cells, FUS regulates cyclin D1 expression via recruitment to the CCND1 promoter and this is 16 
modulated by androgen treatment. 17 
 18 
FUS induces apoptosis. We have shown that increasing FUS expression in cells cycling in 19 
response to androgen results in an increase in the sub-G1 population, which suggests an increase in 20 
apoptosis (Figure 4A and Supplemental Table 1). To confirm whether FUS can influence rates of 21 
apoptosis, caspase 3/7 activity was measured (Figure 4B). Exogenous expression of FUS resulted in 22 
an increase in caspase 3/7 activity of 2.9-fold at 4 days and 34-fold at 8 days in the mibolerone-23 
treated cells.  No such doxycycline-induced increase in caspase activity was evident for the parental 24 
LNCaP-TR2 upon androgen treatment.  We also investigated the downstream apoptotic marker of 25 
PARP cleavage. Western blotting demonstrated a ligand- and FUS overexpression-dependent 26 
 13
increase in cleaved PARP (Figure 4C), which was evident after 4 days treatment. Hence it appears  1 
that increasing FUS expression results in an increase in cell death due to activation of apoptotic 2 
pathways.  3 
 4 
FUS blocks tumor growth in vivo.  Having demonstrated FUS to be a repressor of androgen-5 
dependent proliferation in culture, we went on to investigate the role of FUS in prostate tumor 6 
progression in vivo.  The LNCaP-FUS line was subcutaneously injected into both flanks of castrated 7 
male nude BALB/c mice.  Animals were given bi-daily injections of testosterone until tumors had 8 
reached an average size of approximately 250mm3, upon which (Day 0) animals were split into 9 
experimental groups of ± testosterone and ± doxycycline (Figure 5A).  In the absence of 10 
testosterone tumors did not increase in size during the course of the experiment, in fact some 11 
regression was seen, whereas testosterone promoted a significant increase in growth (T-Test, 7 days 12 
p<0.05).  Addition of doxycycline to testosterone treated mice led to a significant reduction in 13 
tumor volume compared to testosterone alone (p<0.05 at 7 days), with tumor volumes falling to 14 
sizes comparable to those in animals receiving no testosterone. 15 
 To test whether the effects of FUS overexpression are reversible, mice that were treated with 16 
testosterone and doxycycline were monitored for an extended period (Figure 5B).  At day 13 17 
doxycycline was withdrawn and the tumors were found to grow, expanding up to an average of 1.5 18 
times original tumor size at day 29 (p<0.0005).  Doxycycline was re-introduced at day 30 and the 19 
relative tumor volume again regressed, this time in a dramatic fashion to approximately 50% of 20 
maximum size at day 37.  Following animal sacrifice, immunohistochemistry was performed upon 21 
tumor sections to investigate the expression of markers of proliferation and apoptosis.  The number 22 
of cells expressing the mitotic marker phospho-histone H3 was found to be significantly decreased 23 
following exogenous FUS expression whereas markers of apoptosis (active caspase 3 and cleaved 24 
PARP) were significantly up-regulated (Figure 5C and Supplemental Figure 4).  25 
 26 
 14
FUS expression is inversely correlated with Gleason grade, survival and bone metastasis.  To 1 
determine whether alterations in FUS expression are associated with prostate cancer progression, 2 
immunohistochemistry was performed on prostate cancer tissue microarrays (examples of staining 3 
in Supplemental Figure 5). Sections were scored for primary Gleason grade and epithelial cells 4 
scored for the number of cells positive for nuclear FUS staining per field (Figure 6A) and the 5 
intensity of nuclear staining (Figure 6B).  An inverse correlation of FUS expression with Gleason 6 
grade, a determinant of aggression of prostate cancer by histology, was found using both scoring 7 
methods for all grades except for BPH versus primary Gleason grade 3.  Analysis of patient survival 8 
and data on the presence of bone metastases found no significant correlation with the number of 9 
cells positive for FUS. FUS nuclear intensity, however, showed significant correlation with the 10 
presence of bone metastases at the time of biopsy (data available for 77 patients with confirmed 11 
absence of bone metastases and 37 with confirmed bone metastases), with patients with high levels 12 
of FUS significantly less likely to present with bone metastases (Mann-Whitney, two-tailed p-13 
value=0.0325).  Further, a significant difference in patient survival was observed. Patients with high 14 
FUS expression show significantly longer survival than patients with low FUS expression, with 15 
mean survival increasing from 70.8 to 91.8 months and median from 57 to 109.2 months in the high 16 
expressers versus the low expressers (Figure 6C and Table 1).  17 
 18 
Discussion 19 
Prostate cancer growth is almost always dependent upon the AR pathway and therefore 20 
identification of downstream targets critical for growth is important for the further characterization 21 
of this disease.  In an attempt to identify novel androgen-regulated targets, we performed a 22 
proteomic screen on the LNCaP prostate cancer cell line following stimulation with androgen.  One 23 
of the proteins found to be significantly regulated was the RNA-binding protein FUS.  Addition of 24 
androgen was found to result in a decrease in FUS expression at the RNA and protein level.  25 
Perrotti et al. have shown that FUS is regulated at the protein level by c-jun (21), which targets the 26 
 15
protein to the proteasome.  Velasco et al. reported regulation of c-jun by androgen (25), and in 1 
support of this we saw upregulation of c-jun protein within 8 hours of androgen treatment 2 
(Supplemental Figure 1A). Since c-jun upregulation precedes the observed decrease in FUS levels, 3 
we hypothesised that androgens may induce FUS degradation via increasing c-jun. However, 4 
knock-down of c-jun or treatment with proteasomal inhibitors did not reduce the androgen-5 
dependent down-regulation of FUS.  We therefore conclude that the regulation of FUS in response 6 
to androgen is predominantly at the transcriptional level. 7 
Since FUS levels are decreased by growth-promoting androgen treatment we hypothesized 8 
that FUS may be a repressor of prostate cancer growth.  In stably transfected LNCaP cells, we 9 
found exogenous FUS expression significantly inhibits cell growth, causes G1 arrest and promotes 10 
apoptosis.  The AR is known to regulate factors important in cell cycle progression and appears be 11 
particularly important in G1/S progression since androgen depletion results in G1 arrest (24).  In 12 
agreement with this we also found LNCaP cells to arrest in G1 following removal of androgen 13 
whereas addition of androgen resulted in an increase in the number of cells progressing to S and 14 
G2/M.  Overexpression of FUS, however, blocked the effects of androgen, leading to G1 arrest and 15 
also an increase in the sub-G1 population.  Increased caspase 3/7 activity and an increase in the 16 
levels of PARP cleavage confirmed that this sub-G1 population contained apoptotic cells. Hence 17 
FUS appears to promote apoptosis in prostate cancer cells.  18 
Analysis of cell cycle regulators revealed that manipulation of FUS levels is associated with 19 
altered expression of several factors important in G1/S transition, specifically cyclin D1, CDK6 and 20 
p27. It is known that cyclin D1 and p27 are androgen targets, and that an increase in cyclin D1 and 21 
a decrease in p27 promote G1 transition (22-24). Our observed reduction in the expression of this 22 
cyclin and the increase in p27 following exogenous expression of FUS suggests that FUS induces 23 
G1 arrest and thus affects androgen-dependent proliferation, at least in part, via modulation of these 24 
factors. Recently, FUS was demonstrated to be directly recruited to the regulatory regions of 25 
CCND1, which encodes cyclin D1, by ncRNA which is transcribed from various points on the 5’ 26 
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upstream region. This recruitment leads to interference with transcriptional complex formation 1 
hence decreased expression of cyclin D1 (12). The regulation of cyclin D1 in response to FUS over-2 
expression or knock-down was found to be at the RNA level (Figure 3B). Further, chromatin 3 
immunoprecipitation revealed FUS binding to ncRNA-expressing regions of the CCND1 promoter 4 
in the absence of androgen, which was abrogated by androgen treatment. This data therefore fits 5 
with the mechanism of regulation proposed by Wang et al. (12) and suggests that androgen 6 
withdrawal-mediated repression of cyclin D1 expression is via alterations in recruitment of FUS to 7 
the CCND1 promoter. It thus appears that cyclin D1 is a target of both androgens (22-24) and FUS 8 
(12) (and data herein). We have shown that FUS levels are regulated by androgens, and others have 9 
shown that cyclin D1 itself is a corepressor of the androgen receptor (26). It is therefore possible 10 
that complex functional interactions between FUS, the androgen receptor and cyclin D1 which 11 
merit further investigation. Notwithstanding this, our data demonstrate that manipulation of FUS 12 
levels influences the levels of a number of key cell cycle regulatory proteins, indicating that FUS 13 
may be a critical link between androgen signalling and cell cycle progression. 14 
Our data from both in vitro and in vivo systems demonstrates FUS to have characteristics 15 
suggestive of a putative tumor suppressor. FUS expression in prostate tumor samples was inversely 16 
correlated with Gleason grade and analysis of patient data demonstrated that those with high 17 
expression levels of FUS had longer survival rates and were less likely to have bone metastases (the 18 
primary cause of morbidity in prostate cancer patients), suggesting that loss of expression may be 19 
important in disease progression. Our study in xenograft models suggests that this correlation is not 20 
merely circumstantial, since not only did increasing FUS levels result in decreased tumour growth, 21 
but this effect was also reversible since removing the exogenous expression increased tumour 22 
growth while re-expressing it halved the tumour volume within a week.  23 
From the work presented here, we suggest that androgen signalling down-regulates FUS and 24 
that FUS subsequently regulates factors important in cell cycle progression.  This, combined with 25 
the finding that FUS expression is reduced in advanced stages of prostate cancer, suggests that loss 26 
 17
of FUS may enhance androgen signalling and promote prostate cell growth.  Further, the 1 
demonstration that over-expression of FUS in vivo reduces tumor growth suggests that methods to 2 
manipulate FUS expression could be useful for the treatment of prostate cancer. 3 
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Figure Legends 1 
Figure 1. FUS is down-regulated in response to androgen. LNCaP cells were exposed to 2 
mibolerone (MIB) or vehicle (ethanol, EtOH).  A, Lysates were separated by 2D gel electrophoresis 3 
and proteins visualized using SyproRuby staining.  Significant differences in spot intensity between 4 
treatments were identified using PDQuest v6.2.1 (Biorad) and protein identities determined using 5 
mass spectrometry. B, LNCaP cells were treated for the indicated times, lysates separated by SDS-6 
PAGE and immunoblotting performed. Densitometry was performed upon 3 independent samples 7 
and data normalized to β-actin and expressed relative to 0hrs. C, LNCaP cells were treated for the 8 
indicated times with ligand, RNA harvested and real-time quantitative PCR performed.  9 
 10 
Figure 2. FUS blocks androgen-dependent prostate cell growth. A, The LNCaP-FUS line was 11 
treated ± doxycycline (DOX) + mibolerone (MIB) and images taken with a phase contrast 12 
microscope at the indicated times (bars = 100μm). The effect of FUS over-expression upon 13 
androgen-induced cell proliferation was quantified using WST1 assays. WST1 assays were also 14 
performed upon the parental line, LNCaP-TR2. B, At the indicated time point, cells were fixed, 15 
stained with propidium iodide and cell cycle analyzed by FACs.  Data was analyzed using FlowJo 16 
v8.8.6 (Tree Star).  C, The 4 days FACS data was reanalyzed to exclude the sub-G1 pool. D, 17 
LNCaP cells were transfected with scrambled siRNA or siRNA to target FUS and incubated for 3 18 
days before treatment with different doses of ligand. Cells were left for 3 or 6 days following 19 
treatment with mibolerone (MIB) before WST1 growth assays were performed. T-test * p<0.05, 20 
**p<0.005, *** p<0.0005.  21 
 22 
Figure 3. FUS regulates factors involved in cell cycle progression. A, The LNCaP-FUS cell line 23 
was treated + mibolerone and ± doxycycline.  Cells were harvested 72hrs after treatment with 24 
ligand for Western blotting. B, LNCaP-FUS cells treated as for A were harvested 48hrs after 25 
treatment for qRT-PCR analysis of gene expression. C, LNCaP cells were transfected with 26 
 22
scrambled or FUS-specific siRNA.  72hrs after transfection, cells were treated ± mibolerone for 1 
24hrs, RNA harvested and qRT-PCR performed. D, LNCaP cells were treated with androgen for the 2 
indicated times, cells fixed and chromatin immunoprecipitation performed using an antibody 3 
specific for FUS or control IgG.  RT-PCR was performed on a 3 regions of the CCND1 promoter. 4 
T-test * p<0.05, *** p<0.0005. 5 
 6 
Figure 4.  Exogenous FUS expression promotes apoptosis. LNCaP-FUS cells were treated ± DOX 7 
and ± MIB. A, Cells were fixed, propidium iodide stained and FACs analysis used to quantitate the 8 
% number of cells in sub-G1. B, Caspase 3/7 activity was analyzed using the Caspase 3/7-Glo assay 9 
(Promega) and activity normalized to account for changes in cell proliferation. Graph shows fold 10 
change of DOX-treated over vehicle-treated cells for each point. C, Cells were harvested, lysed and 11 
proteins separated by SDS PAGE.  Proteins were visualized using immunoblotting as indicated 12 
 13 
Figure 5. Increasing FUS levels blocks androgen dependent tumor growth in vivo. Male castrated 14 
nude mice were injected subcutaneously with LNCaP-FUS.  The mice were given bi-daily 15 
testosterone injections until tumors had established. A, Mice were split into experimental groups 16 
(Day 0) and relative tumor volume (RTV) measured over 7 days.  Tumor size was measured using 17 
calipers and the relative tumor volumes (RTV) calculated. B, Tumor size of mice in the + 18 
testosterone + doxycycline group were monitored for an extended time course during which time 19 
doxycycline was removed (day 13) and re-administered (day 31). Mean RTV ± 1SE. C, 20 
Immunohistochemistry was performed on sections derived from the xenograft tumors to investigate 21 
cells positive for markers of proliferation and apoptosis. The number of positive cells were counted 22 
and expressed as a percentage of the total cell number of cells in 5 randomly chosen fields of view 23 
in at least 2 independent tumors (Mean ± SE shown). T-test * p<0.05, ** p<0.005.  24 
 25 
 23
Figure 6. FUS expression is inversely correlated with Gleason grade and directly correlated with 1 
patient survival. Immunohistochemistry was performed upon three human prostate cancer tissue 2 
microarrays and cores scored for A, the number of cells positive for FUS or B, FUS staining 3 
intensity and expressed in relation to grade. C, Kaplan Meier graph to show the correlation between 4 
FUS staining intensity and patient survival time (months). * p<0.05, **p<0.005, *** p<0.0005 (chi-5 
squared test). 6 
 7 
Table 1. FUS expression is correlated with patient survival. The intensity of FUS staining was 8 
correlated with patient data and median and mean survival times calculated. 9 
 10 
 11 
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